Showing results (81-90 of 104) with videos related to

Sort By:
Pageof 11
Oncoimmunology|July 30, 2016
Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapyKei Ishibashi, Takumi Kumai, Takayuki Ohkuri, et al.
Idcases|March 18, 2026
Inflammatory exacerbation of hepatic alveolar echinococcosis during dupilumab therapy: A case reportTakumu Hasebe, Honami Tanaka, Masami Abe, et al.
Breast Cancer (Tokyo, Japan)|July 6, 2026
Abemaciclib plus endocrine therapy in chemotherapy-treated patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancerKazutaka Narui, Kana Miyahara, Yukari Uemura, et al.
International Journal of Clinical Oncology|April 23, 2021
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)Kenjiro Aogi, Kenichi Watanabe, Masahiro Kitada, et al.
Breast (Edinburgh, Scotland)|December 20, 2020
Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancerJunji Tsurutani, Fumikata Hara, Masahiro Kitada, et al.
Breast Cancer (Tokyo, Japan)|September 7, 2021
Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancerNaruto Taira, Kosuke Kashiwabara, Junji Tsurutani, et al.
Eclinicalmedicine|August 7, 2024
Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trialMasato Takahashi, Yuichiro Kikawa, Kosuke Kashiwabara, et al.
Breast Cancer Research and Treatment|June 26, 2024
Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial)Takayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, et al.
The Journal of Experimental Medicine|September 24, 2021
CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytesAkemi Kosaka, Kei Ishibashi, Toshihiro Nagato, et al.
Oncology Letters|April 12, 2021
The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancerSatoshi Okazaki, Takaaki Sasaki, Shunsuke Yasuda, et al.
Pageof 11